Inspiration 360

Core to our company is a holistic vision of health, which includes: full healthcare processes, diagnostics, and treatments as a tool to improve and support patient care.

We empower doctors with disruptive tools and technologies that help them in their clinical and diagnostic processes and with dispensing medicine. This is the future medical treatments.

We’re disrupting traditional solutions by analysing and reversing clinical programming processes. We started with pharmacological processes, because our team understands that prescriptions and drugs are the basis upon which physicians build their therapeutic treatments of patients.

We use innovative technologies that precisely define a patient’s pathological status and scenario. From there, solutions are entirely determined by the different medical societies and existing clinical databases. Only the best therapeutic strategies that are supported with extensive clinical data are included in our knowledge base and adapted to the patient’s conditions are used. This guarantees the best solution to a patient’s health concern.

Artificial intelligence is used to enhance the patient’s treatment. The use of AI and algorithms mean that each patient’s individual case is being analyzed, including their clinical history.

We greatly enhance the patient’s clinical data with genomic information, which is adapted to their unique metabolic processes. This is key to determining the best drug for each patient. Ultimately, enhancing all medical processes and further enabling successful outcomes through the treatments offered.

With a holistic approach to medicine, we are interested in generating and furthering personalized medicine, our technology is founded and developed on this principle.

As our technology is intelligent, specifically AI, we are always developing and refining our offerings to better serve and support doctors and patients. New applications and services will allow us to advance therapeutic processes to treat diseases and most importantly patients more effectively.

Our extensive pharmaceutical knowledge enables us to identify new components involved in the pathogenesis of disease. Our system works to identify new therapeutic targets based upon the patient’s conditions and ultimately offer the best available treatment for each patient.

B2B for Professionals

Pharmacotherapeutic databases

Marketed August 2018

App Pharma

Marketed July 2021

Smart Clinical Dashboard for EHRs

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Smart Clinical Dashboard for HPMSs

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Smart Clinical Dashboard for Pharmacies

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Healthcare professionals and pharmacists

Medical Workstations / POS at pharmacies

B2C for Patients

Smart Automated Telemedicine Platform

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Smart COVID-19

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Smart online Pharmacy

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Smart Health Marketplace

In prototype TRL5: Q2 2022 / Ending: Q4 2022

Patients and customers

Personal devices

Technology

We use state-of-the-art Open technologies that allow us to offer disruptive tools, that allow solutions totally focused on the user with persistent, reactive operation, with total security of operation, privacy and evolution.

Security

Safety in clinical processes is our first premise in the services we offer, adopting the standards that allow us to structure, standardize and secure all the processes according to the most demanding international regulations.

 Roadmap

Our medical solutions for healthcare:

Pharmacological databasesAPP Pharma APP Smart Clinical Dashboard for EHRs APP Smart Clinical Dashboard for HPMSs APP Smart Clinical Dashboard for PharmaciesAPP Smart Automated Telemedicine PlatformAPP Smart COVID-19APP Smart online PharmacyAPP Smart Health MarketplaceApril 2021Q4 2022Q4 2022Q4 2022Q4 2022Q4 2022Q4 2022Q1 2023Q1 2023Q1 2023Q1 2023Q1 2023Q1 2023Q1 2023April 2021July 2021

We already have a deployment plan with many of the technologies and knowledge engines in place.

Our financial forecast is based on our deployment plan with the tools and platforms we already have in place as well as planned modules.

Once our core applications for intelligent health management are deployed, we will offer virtual training for online purchasing health treatments and the dispensing of pharmaceuticals.

We believe the future of our disruptive applications is bright, with our core focus being to further empower medical, paramedical and pharmaceutical professionals with advanced user assistance interfaces with total security while also supporting complete health in our patients.

The use of avatars and AI-powered virtualization technologies will be one of the following milestones to be implemented in healthcare, and our applications are ready for it.

  • AI-Emergency call
  • AI-Electronic medical record
  • Drug AI-Discovery
  • Firmware to control a new generation of medical devices

 Our solutions

App Pharma

App Pharma

  • To view all the characteristics of the drugs and medications that are marketed in Spain in a consolidated and structured way.
  • Currently used by over 12 million patients across three separate contracts.

Read More

Key projects

VDM Health is currently offering a pharmacological prescription assistance service to three of the 17 autonomous communities in Spain, with a population* of 12,114,845 inhabitants who spend an accumulated amount of €16,831 million and €2,780 million on medical services. in pharmacy services.
*data year 2020

Autonomous Region of La Rioja

La Rioja is the smallest of the seventeen autonomous communities in Spain, with a GDP of €8,129 million, 316,197 inhabitants and an area of ​​5,045 km2.

 

  • It makes 63.6% of public health spending on hospital and specialized services of the total medical spending of the community.
  • It makes 15.6% of public health expenditure in pharmacy of the total medical expenditure of the community.
  • Medical expenditure per inhabitant of €483 million
  • Pharmacy spending of €75 million
  • €1,535 of medical expenses per inhabitant

Autonomous Region of Valencia

Valencia is the fourth autonomous community in Spain, with a GDP of €216.527 million, 5,045,885 inhabitants and an area of ​​23,255 km2.

 

  • It makes 59.6% of public health spending on hospital and specialized services of the total medical spending of the community.
  • It makes 18.5% of public health expenditure in pharmacy of the total medical expenditure of the community.
  • Medical expenditure per inhabitant of €7,386 million
  • Pharmacy spending of €1,369 million
  • €1,477 of medical expenses per inhabitant

Autonomous Region of Madrid

Madrid is the third autonomous community in Spain, with a GDP of €216.527 million, 6,752,763 inhabitants and an area of ​​8,028 km2.

 

  • It makes 69.4% of public health spending on hospital and specialized services of the total medical spending of the community.
  • It makes 14.9% of public health expenditure in pharmacy of the total medical expenditure of the community.
  • Medical expenditure per inhabitant of €8,962 million
  • Pharmacy spending of €1,336 million
  • €1,340 of medical expenses per inhabitant